Skip to main content
placeholder image

A randomized, controlled, open-label, phase 2 study of cemiplimab �� RP1 in patients with advanced cutaneous squamous cell carcinoma (CERPASS).

Journal Article


Abstract


Publication Date


  • 2022

Citation


  • Haydon, A. M., Khushalani, N. I., Robert, C., Brungs, D., Collichio, F. A., Colevas, A. D., . . . Migden, M. R. (2022). A randomized, controlled, open-label, phase 2 study of cemiplimab �� RP1 in patients with advanced cutaneous squamous cell carcinoma (CERPASS).. Journal of Clinical Oncology, 40(16_suppl), tps9593. doi:10.1200/jco.2022.40.16_suppl.tps9593

Web Of Science Accession Number


Start Page


  • tps9593

End Page


  • tps9593

Volume


  • 40

Issue


  • 16_suppl

Place Of Publication


Abstract


Publication Date


  • 2022

Citation


  • Haydon, A. M., Khushalani, N. I., Robert, C., Brungs, D., Collichio, F. A., Colevas, A. D., . . . Migden, M. R. (2022). A randomized, controlled, open-label, phase 2 study of cemiplimab �� RP1 in patients with advanced cutaneous squamous cell carcinoma (CERPASS).. Journal of Clinical Oncology, 40(16_suppl), tps9593. doi:10.1200/jco.2022.40.16_suppl.tps9593

Web Of Science Accession Number


Start Page


  • tps9593

End Page


  • tps9593

Volume


  • 40

Issue


  • 16_suppl

Place Of Publication